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iAbstract
Purpose: AAZTA (1,4-bis (carboxymethyl)-6-[bis (carboxymethyl)]amino-6-
methylperhydro-1,4-diazepine) based chelators were initially developed in the
context of magnetic resonance imaging. First radiochemical studies showed the
capability of AAZTA to form stable complexes with radiolanthanides and moderately
stable complexes with 68Ga. For a systematic comparison of the labelling capabilities
with current diagnostic and therapeutic trivalent radiometals, AAZTA5 (1,4-bis
(carboxymethyl)-6-[bis (carboxymethyl)]amino-6-[pentanoic-acid]perhydro-1,4-
diazepine) was synthesized representing a bifunctional version with a pentanoic acid
at the carbon-6 atom. To evaluate the effect of adding a targeting vector (TV) to the
bifunctional chelator on the complex formation, AAZTA5-TOC was synthesized,
radiolabeled and tested in comparison to the uncoupled AAZTA5.
Methods: AAZTA5 was synthesized in a 5-step synthesis. It was coupled to the cyclic
peptide TOC (Phe1-Tyr3 octreotide) via amide bound formation. AAZTA and AAZTA5-
TOC complex formations with 68Ga, 44Sc and 177Lu were investigated at different pH,
temperature and precursor amounts. Stability studies against human serum, PBS
buffer, EDTA and DTPA were performed.
Results: AAZTA5 and AAZTA5-TOC achieved quantitative labelling (> 95%) at room
temperature in less than 5 min with all three nuclides at pH ranges from 4 to 5.5
with low precursor amounts of 1 to 10 nmol. [44Sc]Sc-AAZTA5 complexes as well as
[44Sc]Sc-AAZTA5-TOC were completely stable. The 177Lu complexes of AAZTA5 and
AAZTA5-TOC showed high stability comparable to the 44Sc complexes. In contrast,
the [68Ga]Ga-AAZTA5 complex stability was rather low, but interestingly, [68Ga]Ga-
AAZTA5-TOC was completely stable.
Conclusion: AAZTA5 appears to be a promising bifunctional chelator for 68Ga, 44Sc
and 177Lu with outstanding labelling capabilities at room temperature. Complex
stabilities are high in the case of 44Sc and 177Lu. While [68Ga]Ga-AAZTA complexes
alone lacking stability, [68Ga]Ga-AAZTA5-TOC demonstrated high stability. The latter
indicates an interesting feature of [68Ga]Ga-AAZTA5–labelled radiopharmaceuticals.
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The ongoing development in molecular imaging is focusing more and more on thera-
nostic approaches as they link imaging directly with therapy as well as monitoring of
the treatment (Baum and Kulkarni 2012; Baum and Rösch 2013; Rösch et al. 2017). In
this context, patient-individual dosimetry is important for application of long-lived
therapeutic nuclides. This emphasizes the advantage of a longer-lived PET-nuclide like
44Sc over 68Ga (Khawar et al. 2018; Roesch 2012a; Kerdjoudj et al. 2016).
Most of the commonly used nuclides for PET imaging and therapy are trivalent
metals Me(III), thus have a positive charge of 3 as ions in solution. The most
frequently used bifunctional chelators (BFC) are macrocyclic derivatives based on
DOTA and NOTA. Bifunctionalization of DOTA normally uses one of the acid groups
to connect to the targeting vector (TV). DOTA-conjugated TV’s are typically 68Ga-la-
beled at ca. 95 °C for 10–15 min to achieve high labelling yields (Tsionou et al. 2017;
Price and Orvig 2014; Roesch 2012b). NOTA- or NODAGA-conjugated analogues
allow 68Ga-labelling at lower temperature, if larger amounts of the labelling precursor
are utilized, yet for many compounds at lower concentration heating to 95 °C is com-
mon to achieve fast and quantitative labelling (Eisenwiener et al. 2002). For theranostic
strategies with 177Lu only DOTA can be used, since NOTA derivatives are not suitable
for complexing 177Lu. Again, 177Lu-labellig of DOTA-peptides is achieved at tempera-
tures close to 100 °C and optimal labelling pH is around 4.
In addition, some relevant molecular targeting vectors (e.g. based on proteins) are
temperature and pH sensitive. Accordingly, optimal chelators for radiolabeling sensitive
biomolecules with trivalent radiometals (68Ga, 44Sc, 177Lu, 90Y, 213Bi, 225Ac) at room
temperature and pH 5–6 would be extremely important. There are some proper candi-
dates for labelling at room temperature. HBED (Schuhmacher et al. 1992), THP (Berry
et al. 2011), H2dedpa (Boros et al. 2010, 2012), DATA (Waldron et al. 2013; Seemann
et al. 2017; Farkas et al. 2017; Seemann et al. 2015) show the desired labelling capabil-
ities mostly for 68Ga, while THP and DATA have optimum labelling parameters
reaching fast quantitative yields at room temperature on wide pH ranges up to pH 6
(Tsionou et al. 2017). AAZTA5/AAZTACN were reported to provide good labelling with
not only 68Ga, but also 44Sc and 177Lu (Pfister et al. 2015; Nagy et al. 2017; Manzoni
et al. 2012).
In this work, we want to evaluate the AAZTA lead structure in several aspects. First,
a bifunctional derivative (AAZTA5), needed to later covalently attach the chelator to a
TV, was synthesized. Here, our strategy is to replicate the approach we successfully in-
troduced for the DATA chelator (Seemann et al. 2017). Second, we systematically
optimize radiolabeling protocols for Me(III)-AAZTA5 complexes with 68Ga, 44Sc and
177Lu. Third, we correlate labelling yield with Me(III)-AAZTA5 complex stability
in vitro. Fourth, we synthesized a proof-of-principle radiopharmaceutical, namely
AAZTA5-TOC, to again determine radiolabeling efficiency and in vitro stability.Materials and methods
Synthesis of AAZTA5
All standard chemicals were acquired from Sigma-Aldrich, Merck and VWR. AAZTA5
(2,2′-(6-(bis (carboxymethyl)amino)-6-(4-carboxybutyl)-1,4-diazepane-1,4-diyl) diacetic
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via ring opening of nitrocyclohexanon and the full reduction to 2 has been published
before as it is also part of the DATA synthesis (Fig. 1) (Seemann et al. 2017). To form
the fully alkylated AAZTA, the ongoing reaction was catalyzed by KI and moderate
temperatures of 40 °C as well as a huge excess of tert-butyl bromoacetate. By doing so
reaction, yields could be pushed to 50–60%. Analytics of 3 lead to: 1H-NMR (CDCl3,
400MHz, δ [ppm]): 3.65 (s, 4 H); 3.61 (s, 4 H); 3.22 (s, 3 H); 2.99 (d, J = 14.1 Hz, 2 H);
2.85–2.65 (m, 4 H); 2.63 (d, J = 14.1 Hz, 2 H); 2.31 (t, J = 7.4 Hz, 2 H); 1.62–1.52 (m, 4
H); 1.44 (s, 18 H); 1.43 (s, 18 H); 1.25 (m, 2 H); 13C-NMR (CDCl3, 100MHz, δ [ppm]):
174.37 (s); 172.89 (s); 170.94 (s); 80.86 (s); 80.38 (s); 65.29 (s); 63.17 (s); 62.61 (s); 59.39
(s); 52.09 (s); 51.56 (s); 37.34 (s); 34.26 (s); 28.31 (s); 28.25 (s); 25.89 (s); 21.83 (s). To
deprotect the bifunctional acid group, the methyl ester is cleaved with LiOH in
dioxane/water to afford 4, while for the evaluation of the free chelator 5 the protective
tert-butyl groups were cleaved with TFA leaving the methyl ester intact.
Synthesis of AAZTA5-TOC
A standard amide coupling was performed to couple the AAZTA5 to TOC. The TOC
(Phe1-Tyr3-octreotide) was purchased from ABX Germany as H-D-Phe-Cys-Tyr
(tbutyl)-D-Trp (boc)-Lys (boc)-Thr (tbutyl)-Cys-Thr (ol) protected for amide coupling
on the N-terminal amine of D-phenylalanine. As coupling reagent HBTU with an
excess of HOBt was added to a solution of 4 in DMF. DIPEA was used as organic base.
The formation of the active ester could be observed on LC-MS (column used: ZOR-
BAX with 5% to 95% ACN (+ 0.1% MeCOOH)/water (+ 0.1% MeCOOH) in 5 min) as
the mass of 4 (ESI-MS (M +H+): 672.45, 673.45, 674.46) with a retention time of 3.4
min changed to the active ester (ESI-MS (M +H+) with a retention time of 3.8
min. Monitoring the formation of the active ester showed full formation of the
active ester after 15–20 min and the TOC was added. After coupling, all protective
groups were cleaved with TFA. HPLC purification was performed on a LUNA columnFig. 1 Synthesis of the bifunctional chelator AAZTA5: (i) A21, MeOH, in situ; (ii) paraformaldehyde, MeOH,
yield 85%; (iii) Pd (OH)2/C, EtOH, H2, not isolated; (iv) tert-butyl-bromoacetate, K2CO3, ACN, yield (iii/iv) 55%;
(v) LiOH, dioxane/water, yield 80%; (vi) 90% TFA/5% H2O/5% triisopropylsilane (TiS), yield 60% after HPLC
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(+ 0.1% TFA)/79% water (+ 0.1% TFA). The final product AAZTA5-TOC was
collected at a retention time of 15–17 min in an yield of 45% over the coupling
reaction, deprotection and purification. ESI-MS showed the pure product at 1464,6
(M + H)+ (C67H94N13O20S2 predicted 1464,62).Radiolabeling with 68Ga, 44Sc and 177Lu
For radiolabeling with 68Ga a 68Ge/68Ga generator (TiO2-based matrix, Cyclotron Co.,
Obninsk, Russia) was used with acetone post-processing separating iron and zinc
impurities as well as 68Ge breakthrough (Zhernosekov et al. 2007). Radiolabeling with
44Sc was performed with a 44Sc/44Ti generator (Filosofov et al. 2010; Pruszyński et al.
2010) located at the Institute of Nuclear Chemistry in Mainz. 177Lu was provided by itg
Munich following the carrier-free production pathway 176Yb(n,γ)177Yb→ 177Lu (Lebedev
et al. 2000).
Radiolabeling for all radiometals was performed in 1 ml of 0.2M ammonium acetate
buffer pH 4.5 and 5.5. Due to the post processing for 44Sc the nuclide is provided in
0.25M ammonium acetate buffer pH 4 (Pruszyński et al. 2010) and for first studies the
pH was not adjusted above pH 4. With 1 ml labeling volume for 68Ga and 44Sc precur-
sor concentrations of 5 and 10 pmol/l and for 177Lu lower concentrations of 0.5 and 1
pmol/l were used. To show the mild labelling capability of the AAZTA5 chelator, the
reaction temperature was adjusted to 25 °C with a BT 03 heater from HLC BioTech
(Germany). Labelling studies were performed with 50MBq for 44Sc and 100MBq for
68Ga and 177Lu. At different time points of 1, 3, 5 and 10 min aliquots for TLC and
HPLC analytics were taken. The pH was controlled at start of labelling and after label-
ling, was finished.
For reaction control TLC (TLC Silica gel 60 F254 Merck®) with citrate buffer (pH
7) and ammonium acetate buffer (pH 7)/MeOH 50/50 was used and compared to
radio HPLC (Chromolith flush column, water: ACN with 0.1% TFA, 5 to 95%
ACN in 10 min). TLCs were measured in RITA TLC imager (Elysia Raytest). The
citrate TLC showed free radio metal with an Rf of 0.9 and all labelled compound
sticked to an Rf of 0.1 to 0.3. As TLC would show colloidal radiometals sticking to
an Rf of 0.1 to 0.2 as labelled compound, radio-HPLC was used to exclude the
presence of colloidal radiometals, as colloidal radiometals cannot be eluted from
the used HPLC columns.Stability studies
Stability studies were performed in HS, PBS and EDTA/DTPA solution (pH adjusted to
7 by PBS buffer) in triplicate, starting from Me(III)-AAZTA5/ AAZTA5-TOC batches
of > 95% radiochemical purity. Time points were adjusted to the nuclides half-life: for
68Ga 0.5, 1, 2 h; for 44Sc 0.5, 1, 4, 8 h, 24 h; for 177Lu 0.5, 1 and 2 h, 1 and 7 days. Stabil-
ities against HS were also tested for adsorption to HS as fractions of the stability study
at given time points were added to acetonitrile. After precipitation and centrifugation,
the supernatant solution was removed and residue was measured for activity. HS
(human male AB plasma, USA origin) was bought from Sigma Aldrich, PBS was
prepared with a BupH™ Phosphate Buffered Saline Pack (PIERCE), EDTA and DTPA
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a 0.01M concentration.Results
Synthesis of AAZTA5 and AAZTA5-TOC
The established synthesis for DATA5m and DATA5m-TOC (Seemann et al. 2017) was
successfully transferred to AAZTA5 and AAZTA5-TOC. The key step, attaching four
tert-butyl-acetate-arms to the diazepine backbone, was optimized to work in good
yields by forcing the reaction with slightly increased temperatures of 40 °C and the
addition of KI. Without the exchange from bromine to iodine on the tert-butyl bro-
moacetate nearly no alkylation was observed. Even with KI the reaction is still relatively
slow and needs to be stirred over two days. Deprotection of the methyl group on the
AAZTA5 was done similar to that of DATA5m. Purification by extraction (dichloro-
methane against 0.1M NaCO3 in water) gave the pure product ready for coupling in
the dichloromethane phase. Ready for coupling AAZTA5 could be isolated with a yield
of 35% calculated over all reaction steps from the N,N′-dibenzylethylenediamine used
in the first reaction step.
Formation of the AAZTA5 active ester with HBTU (in DMF with 7 eq of DIPEA) was
fast and could be monitored by LC-MS showing the active ester. After 15 min and posi-
tive LC-MS control, the active ester was added to the TOC solved in DMF. After one
night, the DMF was removed and residues were resolved in 95% TFA/2.5% water/2.5%
TiS (triisopropylesilane) to start the deprotection step. Lower concentrations of TFA
with dichloromethane as solvent were not acidic enough to fully deprotect the chelator,
leaving 1–2 tert-butyl groups even after 1 night. After 3–4 h of reaction the TFA were
removed and the residue solved in 80% water/20% acetonitrile for HPLC. Yields after
the HPLC were in a solid range of 30–40%.Radiochemical evaluations with 68Ga
For both the free chelator AAZTA5 as well as the AAZTA5-TOC, radiolabelling with
10 nmol precursor showed an almost quantitative yield of > 98% in less than 5 min;
most of the time reaching > 95% even after 1 min at room temperature (Fig. 2). At 5
nmol of precursor amount, a slower kinetic was observed, but still yielding > 90% after
15 min most of the time, yet reproducibility became a problem. Variation of the pH
from 4.5 to 5.5 showed no difference in the kinetics or the overall yield. Thus, 10 nmol
was found to be the optimal precursor amount to prepare [68Ga]Ga-AAZTA5 and
[68Ga]Ga-AAZTA5-TOC, ready to be investigated in subsequent stability studies.
Stability of [68Ga]Ga-AAZTA5 against HS and PBS were high for 1 h, but decreased
slowly at 2 h to a value of 85% and 79%, respectively. Adding EDTA or DTPA decreased
the stability further up to 40–50% after 2 h. In contrast to the free chelator, the
[68Ga]Ga-AAZTA5-TOC was completely stable against HS, PBS, EDTA and DTPA over
two hours (Table 1).Radiochemical evaluation with 44Sc
Labelling both AAZTA5 and AAZTA5-TOC with 44Sc showed a quantitative yield of >
97% with 10 nmol in less than 5 min, most of the time reaching > 95% even after 1 min,
Fig. 2 Labelling kinetics for lowest precursor amounts to reach reproducible quantitative yields within 10
min at room temperature
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kinetics for the free chelator, still yielding > 95% after 10 min for AAZTA5. In contrast,
radiolabelling with five nmol of AAZTA5-TOC was always > 95% in less than 5 min at
room temperature. Labelling with five nmol was stable enough to use it for stability
studies. Stability studies showed for both the free chelator as well as the AAZTA5-TOC
stability against HS, PBS, EDTA and DTPA over 8 h. [44Sc]Sc-AAZTA5-TOC remained
stable with > 90% in HS and PBS even over 24 h (Table 2).
Radiochemical evaluation with 177Lu
General labelling procedures for DOTA conjugated radiopharmaceuticals with n.c.a.
177Lu showed that DOTA is capable of complexing 177Lu in molar ratios from 1: 5 to 1:
10 for save reproducible quantitative labelling. 100MBq of 177Lu is around 0.1 nmol.
177Lu-labelling with 0.5 nmol AAZTA5 (ratio 1: 5) showed quantitative yields of > 98%
already after 1 min at room temperature. Formation of [177Lu]Lu-AAZTA5-TOC had
lower kinetics, yet also leading to yields of > 95% after 5 min. Both showed rapidTable 1 Radiolabelling data for [68Ga]Ga-AAZTA5, [68Ga]Ga-AAZTA5-TOC, [44Sc]Sc-AAZTA5, [44Sc]Sc-
AAZTA5-TOC after 10 min (15 min for 5 nmol AAZTA5) at room temperature
68Ga-Radiolabelling 44Sc-Radiolabelling
AAZTA5 AAZTA5-TOC AAZTA5 AAZTA5-TOC
pH 4.5 5.5 4.5 5.5 4.0 4.0
5 nmol 92.3 ± 1.8 89.8 ± 2.4 94.3 ± 1.7 91.7 ± 3.5 98.0 ± 0.6 96.9 ± 0.9
10 nmol 98.5 ± 0.8 99.1 ± 0.5 99.0 ± 0.7 98.6 ± 0.9 99.5 ± 0.3 96.7 ± 1.2
Table 2 Stability data for 68Ga, 44Sc and 177Lu complexes of AAZTA5 and AAZTA5-TOC against
human serum, PBS buffer and EDTA and DTPA in PBS buffer in percent of stable complex at
specific time points (% labelled compound compared to free activity found at given time point)
68Ga 44Sc 177Lu
time AAZTA5 AAZTA5-TOC time AAZTA5 AAZTA5-TOC time AAZTA5 AAZTA5-TOC
HS 30min 93.0 ± 0.8 98.1 ± 0.2 1 h 93.7 ± 0.9 95.1 ± 0.6 1 h 99.8 ± 0.1 92.5 ± 1.9
1 h 92.7 ± 1.3 96.9 ± 0.2 4 h 94.3 ± 1.7 94.3 ± 0.8 2 h 99.7 ± 0.1 92.3 ± 2.6
2 h 85.3 ± 3.4 95.0 ± 0.3 8 h 93.2 ± 1.1 95.0 ± 1.1 24 h 99.9 ± 0.1 91.5 ± 2.1
24 h 91.3 ± 1.8 93.8 ± 1.0 7 d 82.5 ± 3.2 86.3 ± 3.2
PBS 30min 97.5 ± 1.0 99.1 ± 0.2 1 h 95.3 ± 0.9 97.3 ± 0.5 1 h 97.8 ± 0.5 92.0 ± 1.4
1 h 88.7 ± 0.5 99.2 ± 0.1 4 h 92.7 ± 1.3 98.5 ± 0.9 2 h 98.6 ± 0.4 93.5 ± 1.3
2 h 78.5 ± 4.5 99.3 ± 0.1 8 h 95.9 ± 1.2 96.7 ± 1.4 24 h 99.1 ± 0.6 91.0 ± 2.2
24 h 96.0 ± 0.8 94.7 ± 1.6 7 d 96.0 ± 0.8 93.1 ± 1.8
EDTA 30min 93.0 ± 0.2 98.9 ± 0.4 1 h 93.7 ± 1.3 96.0 ± 0.4 1 h 98.9 ± 0.2 95.7 ± 2.4
1 h 50.3 ± 7.4 99.4 ± 0.2 4 h 90.0 ± 3.2 97.6 ± 0.7 2 h 97.9 ± 0.3 95.1 ± 2.6
2 h 49.5 ± 2.5 99.6 ± 0.1 8 h 92.3 ± 2.1 96.9 ± 1.0 24 h 79.2 ± 2.9 86.8 ± 2.6
24 h 91.9 ± 1.8 95.4 ± 2.1 7 d 48.9 ± 1.5 77.5 ± 2.3
DTPA 30min 84.3 ± 0.9 97.8 ± 0.2 1 h 94.3 ± 0.9 98.7 ± 0.3 1 h 99.1 ± 0.2 98.9 ± 0.5
1 h 78.0 ± 1.4 99.4 ± 0.1 4 h 92.5 ± 0.5 98.9 ± 0.7 2 h 99.1 ± 0.1 96.2 ± 3.2
2 h 45.7 ± 1.3 99.6 ± 0.3 8 h 93.8 ± 1.2 96.9 ± 1.5 24 h 80.4 ± 5.4 82.8 ± 4.7
24 h 93.4 ± 1.1 92.6 ± 3.2 7 d 59.0 ± 14.3 72.9 ± 5.6
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the same for pH 4.5 and 5.5. Labelling of 500MBq 177Lu with 5 nmol precursor (for
stability studies) were also performed yielding > 98% after 1 min reaction time at room
temperature (Table 3).
Stability studies showed for both the free chelator as well as the AAZTA5-TOC good
stabilities of > 90% against HS and PBS over 24 h. Stabilities against EDTA and DTPA
were slightly lower with > 85% after 24 h. Longer studies of 7 d proved good stability
against PBS with > 90% and a small degradation in HS with > 85% (mostly adsorption
on serum proteins, visible by precipitation). 7 d stability values for EDTA and DTPA
gave increasing instability down to 75 and 70% respectively for AAZTA5-TOC and to
60 and 50% respectively for the free chelator.
Discussion
Our experience concerning the synthesis of DATA5m-TOC (Seemann et al. 2017) could
be transferred, with adjustments on the alkylation step, to prepare the free chelator
AAZTA5 and its TOC derivative AAZTA5-TOC in good yields. Radiolabelling with
68Ga showed good and rapid complexation at room temperature with quantitativeTable 3 Radiolabelling data for [177Lu]Lu-AAZTA5 and [177Lu]Lu-AAZTA5-TOC
177Lu-Radiolabelling
pH 4.5 5.5
ligand: Lu ratio AAZTA5 AAZTA5-TOC AAZTA5 AAZTA5-TOC
5: 1 97.9 ± 1.6 98.9 ± 0.5 99.9 ± 0.2 97.7 ± 1.5
10: 1 98.6 ± 0.8 98.7 ± 1.1 99.3 ± 0.7 99.6 ± 0.1
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complexation also worked on pH 5.5 without showing issues forming colloidal 68Ga,
giving the same high yields after 5 min as for pH 4.5. This proves that elevation of the
pH does not affect the labelling in a negative way. This rapid labelling at room
temperature represents a significant advantage of AAZTA5 over DOTA. Second, fast
labelling kinetics of DOTA also demand higher temperatures and precursor amounts
and this demonstrates the most relevant feature of AAZTA5 compared to DOTA-
derivatives.
Stability of the free [68Ga]Ga-AAZTA5 complex was not 100% over the 2 h, releasing
10–15% of the 68Ga against HS and PBS consistent with literature (Waldron et al.
2013; Baranyai et al. 2013). However, and extremely interesting, [68Ga]Ga-AAZTA5-
TOC was completely stable over two hours against HS and PBS, showing a positive
effect of the TOC on the stability of the 68Ga-complex. Due to the short spacer
between the chelator and the TV, this could be a steric influence of the peptide
moiety, but also the contribution of the amide formed in the coupling process may
influence 68Ga coordination. Adding EDTA or DTPA to the PBS increased the in-
stability for AAZTA5, whereas AAZTA5-TOC remained fully stable. It appears to
be necessary to study the impact of moieties other then TOC to further under-
stand this phenomenon.
Rapid and quantitative 44Sc-AAZTA5 complex formation (both AATZA5 and
AAZTA5-TOC) at room temperature with low precursor amounts of five nmol demon-
strate that the AAZTA5 structure is almost ideal for labelling 44Sc. With 100MBq, 68Ga
in contrast to 50MBq 44Sc the effective amount of radiometal used per labelling was
even higher for 44Sc due to its longer half-life. In fact, 50MBq 44Sc contain near double
the nmol of radio metal compared to 100MBq 68Ga. Using half of the precursor
amount on double the nmol radio metal leads to a chelator to radio metal ratio in the
labelling solution that is 4 times lower in the 44Sc labelling than for 68Ga one. In
addition, less precursor is also lowering the chelator concentration in the labelling solu-
tion. Consequently, AAZTA5 and AAZTA5-TOC have outstanding labelling capabilities
for 44Sc. [44Sc]Sc-AAZTA5 and [44Sc]Sc-AAZTA5-TOC were completely stable against
HS and PBS over two times the half-lives of 44Sc and even stable after 24 h. Only
the addition of EDTA and DTPA showed a small release of the 44Sc after 24 h
while the complexes are stable over 8 h. Combining the rapid quantitative radiola-
belling with the good stability, AAZTA5 and AAZTA5-TOC offer optimal labelling
capabilities for 44Sc.
Radiolabelling with 177Lu was performed in equimolar ratios showing that even a ra-
tio of 1: 5 between radiometal and chelator gave quantitative yields. Using ratios of 1:
10, rapid labelling is observed after one minute already at room temperature. Adjusting
the pH to 5.5 had no influence on labelling speed or yields showcasing the same stable
labelling as seen before with 68Ga and 44Sc. Stability over 24 h showed both the
AAZTA5 as well as the AAZTA5-TOC to be stable against HS and PBS with a slight
decomplexation against ETDA and DTPA. After seven days, both complexes stay intact
against PBS whereas the degradation by addition of EDTA and DTPA increases. For
HS, some adsorption to serum proteins was observed by precipitation, while most of
the complex stays intact. Overall, the complex stability is good for PBS and needs
further evaluation in vivo to see the influence of the data from the HS.
Sinnes et al. EJNMMI Radiopharmacy and Chemistry            (2019) 4:18 Page 9 of 10Conclusion
The chimerical triaaza-type AAZTA5 chelator showed rapid quantitative radiolabelling
at room temperature with low precursor amounts up to pH 5.5 for 68Ga, 44Sc and
177Lu. Attaching TOC forming the AAZTA5-TOC had no influence on the labelling
proving the good labelling capabilities can be transferred. The 68Ga complex of
AAZTA5 was not stable as predicted, but AAZTA5-TOC showed complete stability
revealing a strong positive effect of the TV on the stability. This effect needs further
research. The [44Sc]Sc-AAZTA5 complex as well as [44Sc]Sc-AAZTA5-TOC were
completely stable followed by the 177Lu complexes being stable over 24 h with small
degradation after one week. AAZTA5 appears to be an excellent chelator for mild rapid
labelling of both 44Sc and 177Lu forming a theranostic pair.
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